Generic Medicine Info
May be taken with or without food.
AV block (2nd and 3rd degree), sinus bradycardia, bronchial asthma, cardiogenic shock, or overt cardiac failure.
Special Precautions
Inadequate cardiac function, latent cardiac insufficiency, well-compensated heart failure, nonallergic bronchospasm, DM, myasthenia gravis, peripheral vascular disease including Raynaud's disease. Patients undergoing surgery involving general anaesth. Renal or hepatic impairment. May mask signs and symptoms of hyperthyroidism and acute hypoglycaemia. Avoid abrupt withdrawal as it may precipitate thyroid storm, exacerbate angina, HTN and MI. Pregnancy and lactation. Monitoring Parameters Monitor heart rate and BP. Carefully monitor signs/symptoms of angina exacerbation when discontinuing therapy.
Adverse Reactions
Dizziness, fatigue, hallucinations, mental depression, sedation, headache, paraesthesia, malaise, insomnia, sleep disturbances. Bradycardia, peripheral vascular insufficiency, GI disturbances (e.g. diarrhoea, nausea, vomiting). Bronchospasm, rash, pruritus, reversible alopecia, slurred speech, dry mouth, eyes and skin, facial swelling, wt gain, impotence, nasal stuffiness, tinnitus, cough, blurred vision, weakness, sweating, numbness and atypical behaviour.
Drug Interactions
Antagonises β-adrenergic stimulating effects of sympathomimetic agents (e.g. isoproterenol). Additive hypotensive effects w/ diuretics or other hypotensive drugs, phenothiazines, reserpine. Additive negative effects on SA or AV nodal conduction w/ cardiac glycosides, nondihydropyridine Ca channel blockers. May potentiate and prolong the effects of neuromuscular blockers (e.g. tubocurarine Cl). Reduced antihypertensive effects w/ NSAIDs.
CIMS Class
ATC Classification
C07AA12 - nadolol ; Belongs to the class of non-selective beta-blocking agents. Used in the treatment of cardiovascular diseases.
Disclaimer: This information is independently developed by CIMS based on nadolol from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to CIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, CIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2021 CIMS. All rights reserved. Powered by
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in